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Improving the Effectiveness of Psychological 
Interventions for Depression and Anxiety in 
Cardiac Rehabilitation 
PATHWAY—A Single-Blind, Parallel, Randomized, Controlled Trial of Group 
Metacognitive Therapy
Adrian Wells , PhD; David Reeves, PhD; Lora Capobianco , PhD; Calvin Heal, MSc; Linda Davies, PhD;  
Anthony Heagerty, MD; Patrick Doherty, PhD; Peter Fisher , PhD
BACKGROUND: Depression and anxiety in cardiovascular disease are significant, contributing to poor prognosis. Unfortunately, 
current psychological treatments offer mixed, usually small improvements in these symptoms. The present trial tested for the 
first time the effects of group metacognitive therapy (MCT; 6 sessions) on anxiety and depressive symptoms when delivered 
alongside cardiac rehabilitation (CR).
METHODS: A total of 332 CR patients recruited from 5 National Health Service Trusts across the North-West of England 
were randomly allocated to MCT+CR (n=163, 49.1%) or usual CR alone (n=169, 50.9%). Randomization was 1:1 via 
minimization balancing arms on sex and Hospital Anxiety and Depression Scale scores within hospital site. The primary 
outcome was Hospital Anxiety and Depression Scale total after treatment (4-month follow-up). Secondary outcomes were 
individual Hospital Anxiety and Depression Scales, traumatic stress symptoms, and psychological mechanisms including 
metacognitive beliefs and repetitive negative thinking. Analysis was intention to treat.
RESULTS: The adjusted group difference on the primary outcome, Hospital Anxiety and Depression Scale total score at 4 months, 
significantly favored the MCT+CR arm (–3.24 [95% CI, –4.67 to –1.81], P<0.001; standardized effect size, 0.52 [95% CI, 0.291 
to 0.750]). The significant difference was maintained at 12 months (–2.19 [95% CI, –3.72 to –0.66], P=0.005; standardized 
effect size, 0.33 [95% CI, 0.101 to 0.568]). The intervention improved outcomes significantly for both depression and anxiety 
symptoms when assessed separately compared with usual care. Sensitivity analysis using multiple imputation of missing values 
supported these findings. Most secondary outcomes favored MCT+CR, with medium to high effect sizes for psychological 
mechanisms of metacognitive beliefs and repetitive negative thinking. No adverse treatment-related events were reported.
CONCLUSIONS: Group MCT+CR significantly improved depression and anxiety compared with usual care and led to greater 
reductions in unhelpful metacognitions and repetitive negative thinking. Most gains remained significant at 12 months. 
Study strengths include a large sample, a theory-based intervention, use of longer-term follow-up, broad inclusion criteria, 
and involvement of a trials unit. Limitations include no control for additional contact as part of MCT to estimate nonspecific 
effects, and the trial was not intended to assess cardiac outcomes. Nonetheless, results demonstrated that addition of the 
MCT intervention had broad and significant beneficial effects on mental health symptoms.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: ISRCTN74643496.
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Cardiovascular disease (CVD) is the most common noncommunicable disease1 and makes the largest contribution to morbidity and mortality worldwide. 
The psychological impacts of CVD are substantial, with 
anxiety and depression affecting up to one-third of people 
with CVD and linked to increased future cardiac events, 
poorer quality of life, greater health care costs, and poorer 
long-term psychological adjustment.2,3 The effective man-
agement of anxiety and depression is therefore important. 
Several trials have evaluated the effect of antidepressant 
drugs and psychotherapy on depression in CVD, including 
the CREATE (Canadian Cardiac Randomized Evaluation 
of Antidepressant and Psychotherapy Efficacy Trial)4 and 
ENRICHD (Enhancing Recovery in Coronary Heart Dis-
ease)5 trials, but the effect for psychological therapy on 
depression symptoms was nonsignificant or small.
The Cochrane review6 and meta-analysis published 
in 2017 included 35 randomized, controlled trials of 
10 703 people with CVD treated for anxiety and depres-
sion using a variety of psychological interventions com-
pared with usual care. The majority of studies (23 out of 
35) evaluated multifaceted interventions including mul-
tiple therapy components. There was evidence of reduc-
tions in anxiety (pooled standardized mean difference 
[SMD], –0.24 [95% CI, –0.09 to –0.38]) and depression 
(pooled SMD, –0.27 [95% CI, –-0.15 to –0.39]), but low 
evidence quality means there is considerable uncertainty 
about the effects observed.
Metacognitive therapy (MCT7) is a theory-based, struc-
tured treatment approach that may be particularly suited 
to addressing the psychological needs of patients with 
CVD. Unlike other therapies, MCT does not require an in-
depth analysis and challenging of the content of patients’ 
worries, which in the CVD context are often realistic.8 
MCT focuses on enabling patients to regulate repetitive 
negative thinking cycles such as worry and rumination 
and other unhelpful behaviors that research shows main-
tain anxiety and depression. Results from randomized, 
controlled trials in mental health settings demonstrate 
that MCT is a highly effective treatment for anxiety9 and 
depression10 and may be more effective than cognitive 
behavior therapy.11 An important question is whether 
such effects might translate to mental health symptoms 
in patients with CVD. Cardiac rehabilitation (CR) ser-
vices may be particularly interested in implementing MCT 
rather than other approaches because it is brief, is highly 
structured, and can be delivered in groups irrespective of 
the nature of psychological problems. Delivering such an 
intervention within CR services has the added value of 
availability of specialist cardiac knowledge while avoiding 
delay and potential stigma associated with a secondary 
mental health referral.
In this article, we report the results of the PATHWAY 
trial, the first large-scale trial of group-MCT in patients 
with CVD patients. We aimed to evaluate if the addition 
of MCT to usual clinical management (CR) improved 
depression and anxiety outcomes. CR in the United King-
dom is offered routinely in a group setting to patients 
after a cardiac event, reduces mortality and hospital 
readmissions, and improves quality of life.12 However, the 
impact on anxiety and depression is small. CR consists 
of exercise sessions, education and stress management 
techniques directed at improving CVD risk profiles, physi-
cal fitness, and psychological functioning.13 The psycho-
logical components are not standardized and vary by CR 
program but may include counseling, relaxation, medita-
tion, and cognitive challenging of negative thoughts.
Clinical Perspective
What Is New?
• A psychological treatment called metacognitive 
therapy was evaluated for the first time in the treat-
ment of anxiety and depression in patients with car-
diovascular disease.
• The treatment improved anxiety and depression 
symptoms when added to usual cardiac rehabili-
tation. Compared with usual care, there were also 
greater improvements in trauma symptoms, beliefs 
about thinking, and unhelpful thinking styles.
• The effect sizes were medium to large, compare 
favorably with the best reported outcomes for 
depression, and are better for anxiety than those 
obtained in earlier cardiovascular disease studies.
What Are the Clinical Implications?
• Anxiety and depression can be effectively managed 
using group metacognitive therapy in patients with 
cardiovascular disease.
• The addition of group metacognitive therapy to car-
diac rehabilitation is well-tolerated and does not 
impact negatively on clinic attendance.
• Metacognitive therapy is deliverable by non–mental 
health specialists and could improve psychological 
outcomes for patients with cardiovascular disease.
Nonstandard Abbreviations and Acronyms




HADS Hospital Anxiety and Depression Scale
IES-R Impact of Event Scale–Revised
MCT metacognitive therapy
MCQ-30 Metacognitions Questionnaire 30
MI multiple imputation
RA research assistant
SMD standardized mean difference
SpACE Spatial Attention Control Exercise
VAS visual analogue scale
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We implemented a pragmatic trial with the primary 
hypothesis that the addition of group-MCT to usual CR 
is more effective than CR alone in alleviating symptoms 
of anxiety and depression in patients with CVD between 
baseline and 4-month follow-up. For maximal reach, we 
did not restrict the study to patients with CVD with diag-
noseable depression or anxiety disorders. Instead, we set 
a minimal inclusion criterion as presence of mild symptoms 
of anxiety, depression, or both, which could include indi-
viduals with current or previous psychological disorders.
METHODS
Study Design
PATHWAY is a multicenter, 2-arm, single-blind randomized, con-
trolled trial with 4- and 12-month follow-up comparing group-
MCT plus usual CR (MCT+CR) with usual CR alone. Patients 
were recruited from CR services at 5 National Health Service 
(NHS) Trust hospitals (University Hospital of South Manchester 
NHS Foundation Trust, Central Manchester University Hospitals 
NHS Foundation Trust, East Cheshire NHS Trust, Stockport 
NHS Foundation Trust, and Pennine Acute Hospitals NHS Trust) 
across the North-West of England. Ethical approval was obtained 
from the Preston Research Ethics Committee (REC Reference 
14/NW/0163), along with site-specific approval. Further details 
are presented in the published study protocol.14 The trial is reg-
istered with the ISCRTN registry, No. ISRCTN74643496. The 
data that support the findings of this study are available from the 
corresponding author on reasonable request.
Participants
All eligible patients were referred to CR services and met 
the Department of Health or British Association for Cardiac 
Prevention and Rehabilitation CR eligibility criteria. A summary 
of reasons for referral to CR by group is presented in Table 1. 
Patients were required to have a score of 8 or greater on either 
the depression or anxiety subscale of the Hospital Anxiety and 
Depression Scale (HADS),15 be age 18 years or older, and 
have a competent level of English language comprehension 
(read, understand, and complete questionnaires in English). For 
more details on the inclusion/exclusion criteria, see the study 
protocol.14
All patients referred to the CR program are sent a 
National Audit of Cardiac Rehabilitation assessment pack,16 
which includes a HADS questionnaire,15 to be returned to the 
CR team at CR assessment. Patients who scored 8 or above 
on the anxiety or depression subscale of the HADS were 
screened for eligibility by the CR staff. A score of 8 or greater 
is considered to be the cutoff for mild clinical symptoms and 
yields the optimal sensitivity and specificity for identifying 
clinical caseness.17 Eligible patients were provided with study 
information and contacted by a research assistant (RA) to 
obtain written consent and administer baseline question-
naires before starting CR.
Randomization and Masking
Patients were randomized by computer via a telephone link to 
the Manchester Academic Health Science Center Clinical Trials 
Co-Ordination Unit. Patients were allocated to trial arms in a 
1:1 ratio using a minimization algorithm18 to maximize balance 
between the 2 arms within each hospital site on sex and HADS 
scores (in 3 subgroups: anxiety score ≥8; depression ≥8; anxi-
ety and depression ≥8). The chief investigator, RAs, and trial 
statisticians were masked to treatment allocation throughout 
data collection and analysis. Instances of accidental unmasking 
were recorded to assess their frequency and severity, which 
was routinely reviewed by the Trial Steering Committee.
Interventions
Participation in study arms did not preclude the addition of 
treatments for more severe anxiety and depression that might 
be required and offered by mental health specialists as part of 
the usual CR treatment pathway.
Usual CR
CR programs are group-based programs including group exer-
cise sessions and educational seminars. They vary somewhat in 
content across services, but all offered core components19 as 
part of outpatient provision using group-based delivery by a mul-
tidisciplinary team in hospital or community settings. CR was run 
weekly over a period of 8 to 10 weeks. Educational seminars 
covered topics including lifestyle and medical risk factor manage-
ment. In addition, sites provided elements of psychosocial inter-
ventions including talks on stress management and relaxation. 
All sites delivered sessions on relaxation, which included breath-
ing techniques and progressive muscle relaxation. Seminars on 
stress management varied. Whereas 2 sites delivered psychoed-
ucation on stress, 3 sites incorporated cognitive therapy methods 
(ie, challenging negative thoughts, worry decision tree, behavioral 
activation). In addition, 1 site offered a 4-week stress manage-
ment course as part of CR, which included cognitive therapy 
procedures such as generating and sharing a case formulation 
based on Greenberger and Padesky treatment manual.20
Group-MCT Plus Usual CR
We chose CR staff to administer group-MCT because CR is 
the main point of repeated contact for patients with CVD, and 
our service-user interviews suggested that patients valued their 
relationship with staff. The intervention group received group-
MCT in addition to usual CR (MCT+CR), which consisted of 6 
sessions of group-MCT of 60 to 90 minutes, with 1 session 
scheduled per week.
MCT+CR was delivered by 2o CR professionals at each 
site (ie, physiotherapist, CR nurse, occupational therapists) 
or research nurses. Therapists received 2 days of training in 
group-MCT followed by supervised practice in delivering the 
intervention to a pilot group, and an additional 1-day workshop 
to address difficulties experienced in delivering the intervention. 
Therapists received supervision throughout the trial. Therapist 
adherence to the trial protocol was assessed using a checklist, 
which recorded the components of the protocol implemented 
in each session, if any components had been missed, and if 
so, why. Session adherence scores were computed by counting 
the total number of elements completed in the session.
Group-MCT consisted of helping participants identify trig-
gering thoughts leading to the processes of worry, rumina-
tion, and other unhelpful coping behaviors. They were guided 
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 After revascularization 86 (52.8%) 89 (52.7%)
 Stable heart failure 21 (12.9%) 16 (9.5%)
 Stable angina 17 10.4% 22 (13.0%)
 After implantation of defibrillator 8 (4.9%) 5 (3.0%)
 Heart valve repair/replacement 13 (8.0%) 13 (7.7%)
  Heart transplantation and ventricu-
lar assist device
1 (0.6%) 1 (0.6%)
 Adult congenital heart disease 2 (1.2%) 2 (1.2%)
 Other 1 (0.6%) 0 (0.0%)
Number of previous cardiac events
 None 100 (61.4%) 99 (58.6%)
 1 28 (17.2%) 30 (17.8%)
 2 or more 35 (21.5%) 40 (23.7%)
Type of previous cardiac events
 Heart attack 33 (20.3%) 33 (19.5%)
 Stroke 12 (7.4%) 17 (10.1%)
 Pulmonary embolism 5 (3.1%) 5 (3.0%)
 Aneurysm 2 (1.2%) 2 (1.2%)
 Angina 32 (19.6%) 31 (18.3%)
 Arrhythmia 13 (8.0%) 21 (12.4%)
Comorbidities
 Hypertension 82 (50.3%) 84 (49.7%)
 Type 1 diabetes 5 (3.1%) 0 (0%)
 Type 2 diabetes 32 (19.6%) 35 (20.7%)
 High cholesterol 75 (46.0%) 84 (49.7%)
 Peripheral arterial disease 12 (7.4%) 17 (10.1%)
 Breathing problems or COPD 58 (35.6%) 48 (28.4%)
 Irritable bowel disease 27 (16.6%) 30 (17.8%)
 Arthritis 65 (39.9%) 69 (40.8%)
 Chronic fatigue or fibromyalgia 12 (7.4%) 12 (7.1%)
 Multiple sclerosis 1 (0.6%) 2 (1.2%)
BMI 28.8 (6.2) 29.3 (5.9)
Number of comorbidities 5.4 (2.2) 5.4 (2.0)
Outcome measures
HADS total 18.7 (6.4) 18.5 (6.1)
HADS anxiety* 10.5 (3.8) 10.1 (3.6)
HADS depression* 8.3 (3.7) 8.3 (3.7)
Impact of Event Scale–Revised 33.0 (18.6) 32.0 (18.7)
MCQ-30 63.8 (15.7) 60.0 (16.2)
MCQ-30 negative subscale 13.6 (4.7) 12.4 (4.2)
EQ-5D-5L 0.56 (0.26) 0.61 (0.22)
EQ-5D VAS 54.3 (19.6) 57.6 (18.9)
CAS-1R 408.3 (197.7) 369.0 (181.4)
Data are mean (SD) or number, n (%). Ethnicity ‘other’ refers to Asian Ban-
gladeshi, Asian Indian, Asian Pakistani, any other Asian background, Black Af-
rican, Black Caribbean, any other Black background, mixed White and Black 
African, any other mixed background, and any other ethnic group. BMI indicates 
body mass index; CAS-1R, Cognitive-Attentional Syndrome 1–Revised; COPD, 
chronic obstructive pulmonary disease; CR, cardiac rehabilitation; HADS, Hos-
pital Anxiety and Depression Scale; MCQ-30, Metacognitions Questionnaire 











Table 1. Baseline Demographic and Clinical Characteristics
 
Group-metacog-






Age, y 60.4 (11.7) 60.3 (10.5)
Sex*
 Male 108 (66.3%) 110 (65.1%)
 Female 55 (33.7%) 59 (34.9%)
Hospital site*
 Wythenshawe Hospital (UHSM) 69 (42.3%) 72 (42.6%)
 Macclesfield District Hospital 27 (16.6%) 27 (16.0%)
 Manchester Royal Infirmary (CMFT) 24 (14.7%) 25 (14.8%)
 Stockport NHS Foundation Trust 9 (5.5%) 11 (6.5%)
 Pennine Acute Hospitals NHS Trust 34 (20.9%) 34 (20.1%)
Previous psychological therapies for anxiety or depression
 Yes 56 (34.4%) 61 (36.1%)
 No 107 (65.6%) 108 (63.9%)
Medication for anxiety
 Yes 21 (12.9%) 13 (7.7%)
 No 142 (87.1%) 156 (92.3%)
Medication for depression
 Yes 35 (21.5%) 27 (16.0%)
 No 128 (78.5%) 142 (84.0%)
Race/ethnicity
 White 146 (90.1) 146 (86.9)
 Other 16 (9.9) 22 (13.1)
Employment
 Economically active 39 (23.9%) 48 (28.4%)
 Unemployed 14 (8.6%) 17 (10.1%)
 Retired 68 (41.7%) 65 (38.5%)
 All other 42 (25.8%) 39 (23.1%)
Education
 None 28 (17.3%) 45 (26.6%)
 School/vocational 65 (40.1%) 66 (39.1%)
 Diploma/degree 69 (42.6%) 58 (34.3%)
Civil status
 In relationship 97 (59.5%) 98 (58.0%)
 Separated 44 (27.0%) 39 (23.1%)
 Single 22 (13.5%) 32 (18.9%)
Smoking status
 Never smoked 48 (29.5%) 52 (30.8%)
 Ex-smoker 100 (61.4%) 89 (52.7%)
 Current smoker 15 (9.2%) 28 (16.6%)
Alcohol units per month 16.9 (33.0) 16.2 (28.1)
Age at first cardiovascular event, y
 Younger than 45 21 (13.0%) 24 (14.2%)
 45–54 55 (34.0%) 53 (31.4%)
 55 and older 86 (53.1%) 92 (54.4%)
Reason for referral to CR
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flexibility and control over such patterns of extended negative 
thinking. One such technique is the Spatial Attention Control 
Exercise (SpACE), consisting of directing attention as a means 
of enhancing awareness of thoughts and the capacity for 
independent flexible mental control—for example, focusing on 
sounds that might occur on the right and left while being aware 
of the independence of attention control from the occurrence 
of any internal (thoughts and sensations) and external events. 
The therapist uses the exercise to shape and strengthen more 
adaptive metacognitions and weaken beliefs about the uncon-
trollability of thinking. At the end of treatment, each patient 
received their own “helpful behaviors” prescription summarizing 
what they had learned. Homework practice of techniques was 
a feature throughout, and implementation of treatment followed 
the session-by-session manual.
Data Collection
Patients completed assessments at 3 time points: baseline (pre-
CR), 4 months after randomization (4-month follow-up), and 
12 months after randomization (12-month follow-up). Baseline 
assessments were completed face-to-face with an RA, and a 
range of options were offered for completing follow-up assess-
ments: by mail, face-to-face, or via telephone. Patients received 
£5 cash for completing the baseline assessment and a £10 
shopping voucher for each follow-up assessment returned. All 
outcome measures were collected at each time point. Adverse 
and serious adverse events were further reviewed on a quar-
terly basis at the program’s executive committee meetings.
Outcomes
The primary outcome was the HADS15 total score at 4-month 
follow-up (after treatment). The HADS measures symptoms 
of anxiety (7 items) and depression (7 items). Items are rated 
using a 4-point (0–3) scale, with greater scores indicating 
elevated distress. Scores for each subscale range from 0 
to 21 and can be categorized as normal (0–7), mild (8–10), 
moderate (11–14), or severe (15–21). Secondary outcomes 
were the HADS at 12 months, and other measures at 4 and 
12 months as follows: posttraumatic stress symptoms were 
measured using the Impact of Event Scale–Revised (IES-
R).21 Change in metacognitive beliefs (an underlying psycho-
logical causal variable) was measured with the total score on 
the Metacognitions Questionnaire 30 (MCQ-30)22 and the 
“negative beliefs about thoughts concerning uncontrollability 
and danger” MCQ-30 subscale,22 preselected as represent-
ing the primary mechanism targeted in MCT.7 Quality of life 
was assessed with the EQ-5D-5L (EuroQol 5 dimensions 5 
levels; both the utility score and visual analogue scale [VAS] 
score),23 derived using the recommended methods of the 
National Institute for Health and Care Excellence.24,25 The 
Cognitive-Attentional Syndrome 1–Revised (CAS-1R26) was 
used to measure repetitive negative thinking and unhelpful 
coping behaviors, considered as mechanism variables. Adverse 
events were continuously monitored by the health profession-
als delivering Group-MCT and were reported and assessed as 
related or unrelated to the study. Adverse and serious adverse 
events were further reviewed on a quarterly basis at the pro-
gram’s executive committee meetings. We assessed therapist 
adherence to the MCT intervention using a session-by-session 
checklist completed by the cotherapist. The checklist assessed 
whether or not each of the compulsory elements for the par-
ticular session had been completed.
Statistical Analysis
The trial was designed to detect a SMD between trial arms of 
0.4 in HADS total score at 4-month follow-up with 90% power, 
where 0.4 is in the middle of the range of effect sizes reported 
for other forms of psychological interventions for depression.27 
The first 52 patients constituted an internal pilot study for the 
purpose of ascertaining feasibility of recruitment, ascertaining 
retention, and computing a definitive sample size for the main 
trial.14,28 The pilot sample SD in HADS scores at baseline was 
5.7, and based on this, the retention rate, and other statisti-
cal parameters from the pilot, a total recruited sample of 332 
patients was required to detect an effect of 0.4, equivalent to 
a 2.2-point difference in HADS total score (for full details, see 
Wells et al28).
Analysis was conducted in accordance with a prespecified 
analysis plan detailing the analytic models, primary and second-
ary outcomes, choice of covariates, sensitivity analyses, and all 
other key aspects of the analysis. The plan was finalized and 
approved by the trial steering committee before data analysis or 
unmasking. The primary analyses used intention-to-treat prin-
ciples. For continuous outcomes, a linear mixed effects regres-
sion model was applied incorporating all 3 time points (baseline, 
4 months, and 12 months). Prespecified covariates in the 
model were randomization factors (hospital site, sex, baseline 
total HADS score), age, and medication for depression or anxi-
ety (never taken/currently taking/taken in the past). All other 
potential covariates (Table 1) were below predefined imbalance 
criteria for sensitivity testing (standardized mean difference 
>0.25 or category difference >10% between arms). We applied 
hierarchical regression models with random effects at the levels 
of the patient and the CR (or MCT+CR) course attended. The 
covariance matrix for the model was chosen as either unstruc-
tured or first-order autoregressive depending on whichever 
gave the lowest Bayesian Information Criteria score.29
The effects of the intervention at 4-month and 12-month 
follow-up were examined using the treatment group by time 
point interaction terms from the mixed effects model analysis, 
where time point was a categorical variable to provide indepen-
dent tests of effect at 4 and 12 months. No adjustments for 
multiple testing were applied, and an α-value of 5% was used 
throughout. We ran sensitivity analysis using multiple imputa-
tion (MI) to assess robustness of results against missing values. 
There were few missing values at baseline (1 missing outcome 
value and a maximum of 3 missing values on any covariate); 
therefore, these were imputed by simple regression imputation 
using all available variables at baseline but excluding treatment 
arm. MI was then used to impute missing outcome values at 
4 months and 12 months, using the full set of variables and 
including the interaction term between treatment arm and time 
point (for consistency with the analysis model). We used the 
chained-equations MI procedure and 20 MI datasets.30
All outcome measures demonstrated skewness and kurto-
sis below the threshold of 1.0 specified in our analysis plan, so 
sensitivity against nonnormality was not assessed. The trial eli-
gibility criteria allowed inclusion of participants without clinically 
relevant anxiety provided they had at least mild depression, and 
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these categories at baseline, closely balanced across arms. 
To determine how this may have impacted analysis results 
for HADS anxiety and depression as separate outcomes, we 
conducted sensitivity analyses excluding these individuals. 
Analyses were conducted using Stata version 14.
Role of the Funding Source
The funder of the study had no role in the study design, data 
collection, data analysis, data interpretation, or writing of the 
report. The corresponding author (A.W.) had full access to all 
the data in the study and had final responsibility for the decision 
to submit for publication.
RESULTS
A total of 3808 patients were referred to CR between 
July 13, 2015, and January 12, 2018, of whom 992 had 
an elevated HADS score and were screened for eligibility 
(Figure 1). A total of 193 patients did not meet full eligibil-
ity criteria (eg, not proficient in English), resulting in 799 
eligible patients. Of these, 360 declined to take part, 67 
were uncontactable, 17 no longer met the inclusion cri-
teria (eg, began taking antidepressants, had presence of 
suicidality, experienced symptoms of psychosis), and 23 
started CR before being approached. Consequently, 332 
patients consented to the trial, of whom 163 (49.1%) 
were randomly allocated to MCT+CR and 169 (50.9%) 
to CR. There were 52 incidents of unmasking, all involv-
ing an RA accidently discovering a patient’s allocation. 
For these cases, subsequent collection of follow-up data 
from the patient was undertaken by a different RA still 
masked to allocation. There were no cases of the trial 
statisticians or chief investigator becoming unmasked.
Table 1 provides demographic and clinical data for the 
sample at baseline. The groups were well balanced on 
all measured variables. Of patients in the MCT+CR arm, 
34% were female, compared with 35% of patients in the 
CR arm. In both arms, the mean age was 60 years, and 
exposure to previous psychological therapy was 34% 
and 36%, respectively. HADS total scores were similar 
(18.5 versus 18.7), as were IES-R (32.0 versus 33.0) 
and EQ-5D-5L utility scores (10.6 versus 11.4). Differ-
ences were only a little larger with regard to EQ-5D VAS 
(57.6 versus 54.3), MCQ-30 (60.0 versus 63.8), and 
CAS-1R (369.0 versus 408.3) scores.
The mean intervals between baseline and 4-month 
assessments were similar for both arms (CR, 133.6 
days; MCT+CR, 134.7 days), as were the baseline to 
12-month intervals (369.2 versus 370.0 days).
Figure 2 presents mean HADS total scores and 95% 
CIs for each trial arm at each pretreatment and posttreat-
ment assessment point. The pattern of results shows a 
small gradual linear improvement in scores for the CR 
group, which contrasts with a greater and more rapid 
improvement in MCT+CR. Results of the main analysis 
of primary and secondary end points are summarized in 
Table 2. The adjusted group difference on the primary 
outcome (HADS total score at 4 months) significantly 
favored the MCT+CR arm (–3.24 [95% CI, –4.67 to 
–1.81]; P<0.001; SMD=0.52), as did the difference at 
the 12-month secondary outcome point (–2.19 [95% CI, 
–3.72 to –0.66]; P=0.005; SMD=0.33).
Patients in the MCT+CR arm achieved significantly 
lower mean HADS anxiety subscale score at both 4 
months (–1.67 [95% CI, –2.54 to –0.81]; P<0.001; 
SMD=0.44) and 12 months (–1.35 [95% CI, –2.22 
to –0.48]; P=0.002; SMD=0.34), plus a lower HADS 
depression subscale mean score at 4 months (–1.58 
[95% CI, – 2.37 to –0.79]; P<0.001; SMD=0.47) but 
not at 12 months (–0.85 [95% CI, –1.75 to 0.05]; 
P=0.065; SMD=0.23). Results were similar when 
individuals without clinical levels of baseline anxiety 
or depression scores were excluded: for anxiety, an 
adjusted group difference of –1.70 ([95% CI, –2.75 to 
–0.65]; P=0.001; SMD=0.43) at 4 months and –1.38 
([95% CI, –2.50 to –0.25]; P=0.016; SMD=0.33) at 12 
months; for depression, –1.63 ([95% CI, –2.67 to –0.58]; 
P=0.002; SMD=0.46) and –0.65 ([95% CI, –1.82 to 
0.53]; P=0.281; SMD=0.17), respectively. Most other 
secondary outcomes also favored the MCT intervention: 
the IES-R at 4 months (–4.92 [95% CI, –9.04 to –0.81]; 
P=0.019) but not 12 months (–3.28 [95% CI, –7.92 to 
1.36]; P=0.166); MCQ-30 total scores at both 4 and 12 
months (–8.57 [95% CI, –11.95 to –5.18]; P<0.001; and 
–7.37 [95% CI, –11.24 to –3.50]; P<0.001, respectively); 
MCQ-30 negative beliefs subscale scores at both time 
points (–3.15 [95% CI, –4.16 to –2.14]; P<0.001; and 
–2.35 [95% CI, –3.43 to –1.26]; P<0.001) and the CAS-
1R also at both 4 months (–126.25 [95% CI, –165.83 
to –86.67]; P<0.001) and 12 months (–116.29 [95% 
CI, –159.13 to –73.45]; P<0.001). For the EQ5D utility 
scores, there was no statistically significant difference at 
4 months (0.03 [95% CI, –0.02 to 0.09]; P=0.200) or 
at 12 months (0.03 [95% CI, –0.02 to 0.10]; P=0.201); 
similarly, the difference on the EQ5D-VAS was not signif-
icant at either time point (4 months: 4.62 [95% CI, –0.10 
to 9.34]; P=0.055; 12 months: 0.66 [95% CI, –4.12 to 
5.45]; P=0.786). Sensitivity analysis using MI changed 
the statistical significance of the results for only 1 sec-
ondary outcome, the IES-R at 4 months, which ceased to 
be statistically significant (P>0.05).
Patients in both trial arms attended routine CR sessions 
at their site as members of larger groups (of up to 15) 
including patients with CVD not part of the trial. Patients in 
the MCT+CR arm also attended the trial-specific group-
MCT sessions. Across the trial, a total of 77 group-MCT 
courses were conducted, ranging from 3 at the Stockport 
NHS Foundation Trust to 30 at Wythenshawe Hospital, 
with numbers of trial participants varying from a minimum 
of 1 to a maximum of 7 with a mean of 3.5. Attendance 
at CR exercise sessions was high in both groups, with 
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a mean of 6.0 out of 10 sessions attended by CR arm 
patients and 6.3 by MCT+CR patients, a nonsignificant 
difference (0.34 [95% CI, –0.41 to 1.08]; P=0.374). Mean 
attendance at CR educational sessions was lower (CR 
3.6, MCT+CR 4.0) and also did not differ between groups 
(0.4 [95% CI, –0.43 to 1.23]; P=0.343). Attendance at 
group-MCT was high, with 61% attending 4 or more ses-
sions, and 14% attending 1 to 3 sessions. As both condi-
tions involved treatment (and case management) as usual, 
this meant that additional treatment could be sought. 
Across the follow-up period, 14 patients under CR and 6 
under CR+MCT received new psychological therapy out-
side of CR or MCT; the difference was not statistically sig-
nificant (odds ratio, 0.3230 [95% CI, 0.1307–0.801.29]; 
P=0.106); however, the numbers involved were small.
Strength and Clinical Significance of Treatment 
Effects
To aid in the interpretation of findings, we computed ef-
fect sizes in the form of SMDs between groups at 4- 
Figure 1. Trial profile.
CR indicates cardiac rehabilitation; HADS, Hospital Anxiety and Depression Scale; and MCT, metacognitive therapy.
Figure 2. Unadjusted mean total Hospital Anxiety and 
Depression Scale (HADS) scores at baseline, 4-month 
follow-up, and 12-month follow-up.
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and 12-month follow-ups. SMDs were computed as 
the adjusted mean difference between groups from the 
mixed effects model, divided by the pooled SD of change 
scores from baseline for consistency with Cochrane6,31 to 
enable cross-study comparisons. The effect sizes for pri-
mary and secondary outcomes are presented in Table 2.
In addition, we computed the reliable change index32 
for the HADS total score at the primary 4-month follow-
up. The reliable change index represents the difference 
between 2 measurements made on a single individual that 
would be statistically significant at P<0.05. A Cronbach 
alpha of 0.91 derived from the control sample at 4 months 
was used as the estimate of reliability for a usual CR pop-
ulation, because baseline HADS scores had restricted 
variance as a result of being a study eligibility criterion. 
From this, a reduction of 6 points in an individual’s score 
was defined as statistically reliable improvement, whereas 
an increase of 6 points was defined as reliable worsen-
ing of symptoms. The proportions of patients falling into 
each category by trial arm are presented in Table 3. The 
percentage of patients reliably improved was 21% in CR 
compared with 33% in MCT+CR; the percentages exhib-
iting psychological deterioration were 15% in CR com-
pared with 4% in MCT+CR.
Table 2. Summary of Analyses of Primary and Secondary Outcomes
Group-MCT Plus 




Adjusted difference using  
multiple imputation Effect size* (SMD)
n† mean (SD) n† mean (SD) mean (95% CI) P value mean (95% CI) P value  
HADS total
4 mo 132 14.39 (8.22) 144 17.40 (8.06) –3.24 (–4.67 to –1.81) <0.001 –3.38 (–4.95 to –1.81) <0.001 0.52 (0.29 to 0.75)
12 mo 132 14.98 (8.22) 136 16.73 (7.61) –2.19 (–3.72 to –0.66) 0.005 –2.19 (–3.85 to –0.54) 0.010 0.33 (0.10 to 0.57)
HADS anxiety
4 mo 132 7.87 (4.48) 144 9.27 (4.35) –1.67 (–2.54 to –0.81) <0.001 –1.80 (–2.76 to –0.84) <0.001 0.44 (0.21 to 0.66)
12 mo 132 8.20 (4.63) 136 9.17 (4.14) –1.35 (–2.22 to –0.48) 0.002 –1.40 (–2.37 to –0.44) 0.004 0.34 (0.12 to 0.56)
HADS depression
4 mo 132 6.52 (4.40) 144 8.12 (4.34) –1.58 (–2.37 to –0.79) <0.001 –1.58 (–2.44 to –0.72) <0.001 0.47 (0.24 to 0.71)
12 mo 132 6.78 (4.33) 136 7.57 (4.10) –0.85 (–1.75 to 0.05) 0.065 –0.80 (–1.78 to 0.18) 0.110 0.23 (–0.01 to 0.48
IES-R
4 mo 124 21.96 (19.93) 135 25.97 (19.64) –4.92 (–9.04 to –0.81) 0.019 –4.66 (–9.36 to 0.04) 0.052 0.28 (0.05 to 0.51)
12 mo 119 22.55 (20.36) 127 24.23 (19.79) –3.28 (–7.92 to 1.36) 0.166 –2.54 (–7.70 to 2.62) 0.334 0.18 (–0.08 to 0.44)
MCQ-30
4 mo 124 56.01 (16.33) 135 60.25 (16.15) –8.57 (–11.95 to –5.18) <0.001 –8.31 (–12.16 to –4.46) <0.001 0.60 (0.36 to 0.84)
12 mo 120 56.90 (16.59) 127 60.40 (17.00) –7.37 (–11.24 to –3.50) <0.001 –7.60 (–11.79 to –3.42) <0.001 0.48 (0.23 to 0.73)
MCQ30 Neg
4 mo 124 10.61 (4.22) 135 12.63 (4.67) –3.15 (–4.16 to –2.14) <0.001 –3.28 (–4.41 to –2.15) <0.001 0.74 (0.50 to 0.98)
12 mo 120 11.08 (4.27) 127 12.33 (4.69) –2.35 (–3.43 to –1.26) <0.001 –2.42 (–3.57 to –1.27) <0.001 0.56 (0.30 to 0.80)
EQ5D
4 mo 124 0.64 (0.28) 136 0.64 (0.24) 0.03 (–0.02 to 0.09) 0.200 0.05 (–0.01 to 0.11) 0.070 0.15 (–0.10 to 0.54)
12 mo 118 0.62 (0.28) 127 0.62 (0.27) 0.03 (–0.02 to –0.08) 0.201 0.04 (–0.02 to 0.10) 0.166 0.14 (–0.10 to 0.38)
EQ5D VAS
4 mo 125 64.22 (20.48) 136 62.65 (21.02) 4.62 (–0.10 to 9.34) 0.055 4.64 (–0.72 to 10.00) 0.090 0.23 (–0.01 to 0.46)
12 mo 120 60.40 (24.39) 127 62.69 (22.11) 0.66 (–4.12 to 5.45) 0.786 0.90 (–4.21 to 6.02) 0.729 0.03 (–0.19 to 0.25)
CAS-1R






<0.001 –125.36  
(–169.13 to –81.58)
<0.001 0.73 (0.50 to 0.97)






<0.001 –115.00  
(–169.96 to –69.04)
<0.001 0.58 (0.36 to 0.79)
CAS-1R indicates Cognitive-Attentional Syndrome 1–Revised; HADS, Hospital Anxiety and Depression Scale; IES-R, Impact of Event Scale–Revised; MCQ-30, 
Metacognitions Questionnaire 30; MCQ-30 Neg, Metacognitions Questionnaire 30 negative subscale; MCT, metacognitive therapy; SMD, standardized mean dif-
ference; and VAS, visual analogue scale.
*Adjusted mean difference divided by pooled SD of change scores from baseline.
†Numbers of patients with useable scores varied by outcome.
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Protocol Adherence
Across sites, mean adherence to protocol was high 
at 98.8% (SD = 2.43) but varied across sessions and 
between sites with a range of 50% to 100%. The 
most common deviations were not reviewing home-
work (9 deviations) and not practicing SpACE in ses-
sion (4 deviations).
Adverse Events Reporting
Safety and adverse events (increased suicidality, 
death, self-injury) associated with the treatments were 
monitored throughout the trial. No adverse events 
were reported.
DISCUSSION
This trial demonstrated that 6 sessions of group-MCT 
significantly reduced overall depression and anxiety 
when added to CR, compared with CR alone. Improve-
ment in the primary outcome, HADS total at 4 months 
(after treatment), was maintained at 12 months of follow-
up. The addition of MCT to CR also showed superiority 
compared with CR alone on the majority of secondary 
outcomes, at both 4 months and 12 months.
We used the SMD to interpret the size of the effects 
and for comparison with other study findings. The SMDs of 
0.44 for HADS anxiety and 0.47 for HADS depression at 
4 months in the present study compare favorably with the 
aggregated SMDs reported for anxiety (0.24) and depres-
sion (0.27) across other studies.6 The depression effect 
sizes are similar to the MOSAIC33 trial of collaborative care 
(g=0.45) and the CODIACS34 trial of patient preference 
with a range of treatments offered (g=0.59); however, in 
the current study, we found significant improvements in 
anxiety outcomes that these other studies did not.
With respect to overall psychological distress (HADS-
total), 21% of patients individually improved in CR on the 
basis of the 6-point reliable change index, which increased 
to 33% with the addition of group-MCT. In addition, an 
unexpected finding was that MCT+CR demonstrated 
lower rates of statistically reliable deterioration compared 
with CR at 4 months. However, the reliable change index 
sets a high bar with its criteria of statistically significant 
change within an individual, and possibly underestimates 
the numbers experiencing a clinically meaningful change. 
Nonetheless, these effects suggest 2 areas of benefit. 
First, the provision of MCT lowered both anxiety and 
depression symptom severity. Second, the provision of 
MCT might also reduce the risk of psychological deteriora-
tion. The results at 12 months on HADS total continued to 
show a superiority of the MCT group compared with treat-
ment as usual. Although the SMD was smaller compared 
with the 4-month assessment, the result suggests that a 
significant psychological advantage achieved in the MCT 
condition persisted over the longer term. The addition of 
MCT to CR impacted most of the secondary outcomes. 
Significant differences favoring MCT+CR were found at 4 
months in both HADS anxiety and depression when mea-
sured separately, suggesting that the overall effect reflects 
changes in both subsets of symptoms, although only anxi-
ety maintained a statistically significant group difference 
at 12 months. These results were unchanged when we 
excluded individuals without clinically relevant scores at 
baseline. This suggests that MCT had a similar degree of 
effect on those with or without clinical levels at baseline. 
Similarly, the outcomes for posttraumatic stress disorder 
symptoms (IES-R) favored MCT at 4 months, but the dif-
ference was lost at 12 months. The loss of significant dif-
ferences at 12 months in depression and posttraumatic 
stress disorder symptoms likely reflects the natural time-
course by which these symptoms are known to improve 
over a 6- to 12-month period (Diagnostic and Statistical 
Manual of Mental Diorders, 5th edition).35 Regardless, 
the results suggest broader advantageous effects in the 
MCT+CR group in more rapid improvements of trauma-
related symptoms and depressed mood. We found no 
evidence for an impact on EQ5D utility or VAS scores. 
These outcomes will be explored in more depth as part 
of a health economics analysis that will be the focus of a 
separate publication.
We included measures of psychological mechanism 
variables linked to the underlying model of MCT. These 
included metacognitive beliefs (MCQ-30), the MCQ-30 
subscale of negative beliefs about thoughts on uncon-
trollability and danger, and repetitive negative thinking 
and unhelpful coping strategies assessed with CAS-1R. 
In each case, the addition of MCT to CR led to medium 
to large improvements in outcomes over CR at posttreat-
ment and at 12-month follow-up. Thus, the additional 
treatment appears to have reduced to a greater extent 
maladaptive metacognitive beliefs and repetitive and 
unhelpful coping styles, which are hypothesized mecha-
nisms of psychological disorder.36
The present study sample is large and representative 
of patients in CR. For example, Sever et al37 reported that 
Table 3. Reliable Change in HADS Total Score in Individual 










83 (62.9%) 93 (64.6%) 176 (63.8%)
Improved* 44 (33.3%) 30 (20.8%) 74 (26.8%)
Deteriorated† 5 (3.8%) 21 (14.6%) 26 (9.4%)
Data are n (%). “No reliable change” means not reaching threshold of chang-
ing by at least 6 points; it is not intended to mean no change at all. HADS indi-
cates Hospital Anxiety and Depression Scale; and MCT, metacognitive therapy.
*HADS total score reduced by 6 points or more from baseline.
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66.4% of CR patients with a HADS ≥8 were male, and the 
mean age was 60.77 (SD = 10.53). Such sex and HADS 
data are comparable with our study. They also reported 
that patients with elevated distress had on average 4.90 
(SD = 2.19) comorbid physical illnesses, which is similar 
to the current study, in which patients had on average 5.4.
There are limitations of the present study that should 
be considered when interpreting the findings. Of eligible 
patients, 53% declined participation or were unable to be 
contacted. Although this is a high proportion, it is in line 
with previous studies evaluating psychological interven-
tion in CVD, which report 41% to 68% of eligible patients 
declining or unable to take part.5,34,38 Further research on 
reasons for declining may help to identify important fac-
tors in implementation.
Treatment was delivered by CR staff rather than spe-
cialists in psychological therapies, which may mean that 
group-MCT was not delivered optimally. We attempted to 
mitigate this by offering training and supervision in deliv-
ery of the treatment and providing a detailed treatment 
manual for staff to follow. However, it is notable that the 
effects are smaller than those found in the treatment 
of patients with primary mental health disorders using 
MCT.9–11 The smaller effect might be accounted for by 
the briefer nature of the treatment used here and the 
inexperience of cardiac staff delivering a psychological 
intervention. In addition, disease factors such as physical 
disability and poorer physical health might also impact 
the effects observed.
The provision of group-MCT necessitated greater 
patient contact hours, and we do not know how much 
this contributed to the effects. However, our aim was not 
to address questions on active ingredients of treatment 
but a more pressing need about whether or not depres-
sion and anxiety outcomes could be improved. Last, we 
did not intend to assess the impact on cardiac and physi-
cal health outcomes, which would have required a larger 
sample size, but this is an important question for future 
studies. Because psychological distress can influence 
secondary prevention behaviors, assessment of behav-
ior change should be an important outcome for future 
research in this area.
In conclusion, group-MCT in routine CR appears to be 
safe and effective in reducing anxiety and depression and 
improving psychological outcomes beyond those achieved 
in usual care. The benefits appeared to be stable over a 
12-month follow-up period. The effect sizes are compa-
rable with the best existing study outcomes for depres-
sion, while exceeding other studies in reducing anxiety. An 
implication is that the intervention might be incorporated in 
routine CR as a first-line approach for patients with anxiety 
and depression, with more complex specialist-delivered 
mental health interventions offered subsequently to non-
responders or those requiring additional help. The pres-
ent study did not aim to test cardiac event outcomes, and 
therefore we have tempered our consideration of impli-
cations of the study in this respect. However, our results 
suggest that in patients showing distress symptoms, 
combining MCT with CR reliably improved anxiety and 
depression for 1 in 3, while cutting rates of deterioration in 
others. The psychological benefits and reduced risks could 
be substantial if MCT was offered to the 90 000 patients 
in the United Kingdom commencing CR annually.16 In 
conclusion, group-MCT has the potential to significantly 
improve psychological outcomes in patients with CVD and 
offer added value over standard CR.
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